Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases

Sponsor
Kuopio University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05326750
Collaborator
(none)
200
2
119

Study Details

Study Description

Brief Summary

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Condition or Disease Intervention/Treatment Phase
  • Device: Gamma tACS (40 Hz) over the superior parietal cortex
N/A

Detailed Description

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2032
Anticipated Study Completion Date :
Jul 1, 2032

Arms and Interventions

Arm Intervention/Treatment
Experimental: Real tACS

Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)

Device: Gamma tACS (40 Hz) over the superior parietal cortex
Single session of gamma tACS (40 Hz) over the superior parietal cortex

Placebo Comparator: Sham tACS

Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus)

Device: Gamma tACS (40 Hz) over the superior parietal cortex
Single session of gamma tACS (40 Hz) over the superior parietal cortex

Outcome Measures

Primary Outcome Measures

  1. Changes in Rey Auditory Verbal Learning Test score [Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention]

    Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes. The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance).

  2. Changes in Rey Auditory Verbal Learning Test, recognition [Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention]

    Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance).

  3. Changes in orientation to time and place (MMSE questions 1-10) [Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention]

    10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance).

  4. Changes in Trail Making A & B tests [Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention]

    TMT A & B tests. Time to perform set is recorded.

  5. Changes in INECO Frontal Screening test [Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention]

    Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance)

  6. Changes in phonemic fluency [Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention]

    Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute.

Secondary Outcome Measures

  1. Change in SAI measurements [Baseline (immediately before the intervention), immediately after the last intervention]

    By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission.

  2. Change in SICI measurements [Baseline (immediately before the intervention), immediately after the last intervention]

    By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission.

  3. Change in ICF measurements [Baseline (immediately before the intervention), immediately after the last intervention]

    By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Mild Cognitive Impairment due to Alzheimer's disease

  • Dementia with Lewy Bodies

  • Frontotemporal dementia

  • Idiopathic normal pressure hydrocephalus (iNPH)

Exclusion Criteria:
  • History of seizures

  • Pregnancy

  • Metal implants in the head (except dental fillings)

  • Electronic implants (i.e. pace-maker, implanted medical pump)

  • Age <18 years

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Kuopio University Hospital

Investigators

  • Principal Investigator: Eino Solje, MD, PhD, Kuopio University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eino Solje, MD PhD adj. prof., Kuopio University Hospital
ClinicalTrials.gov Identifier:
NCT05326750
Other Study ID Numbers:
  • KUH5772859
First Posted:
Apr 14, 2022
Last Update Posted:
Apr 14, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2022